Sanofi (SNYNF) Non-cash Items (2009 - 2025)
Sanofi's (SNYNF) quarterly Non-cash Items came in at $4.5 billion in Q2 2025, up 15.95% year-on-year from $3.9 billion in Q2 2024, and up 15.95% quarter-over-quarter from $3.9 billion in Q2 2024.
Sanofi (SNYNF) Non-cash Items (2009 - 2025) Analysis & Trends
Sanofi has disclosed Non-cash Items across 17 years of filings, most recently posting $4.5 billion for Q2 2025.
- Non-cash Items for Q2 2025 came in at $4.5 billion, up 15.95% year-over-year; the trailing twelve-month figure through Jun 2025 was $4.5 billion (up 15.95% YoY), and the FY2023 annual result was $10.3 billion, down 13.25% from the prior year.
- Non-cash Items came in at $4.5 billion for Q2 2025 at Sanofi, up from $3.9 billion in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $11.5 billion in Q4 2022 to a low of $3.9 billion in Q2 2024.
- The 5-year median for Non-cash Items is $5.1 billion (2021), against an average of $6.9 billion.
- Across the five-year window, Non-cash Items jumped 18949.42% in 2021 and retreated 18.57% in 2024, its largest moves.
- Sanofi's Non-cash Items stood at $10.4 billion in 2021, then increased by 9.93% to $11.5 billion in 2022, then slipped by 10.87% to $10.2 billion in 2023, then plunged by 61.96% to $3.9 billion in 2024, then gained by 15.95% to $4.5 billion in 2025.
- The last three Non-cash Items figures came in at $4.5 billion (Q2 2025), $3.9 billion (Q2 2024), and $10.2 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.51 Bn |
| Jun 30, 2025 | 4.51 Bn |
| Jun 30, 2024 | 3.89 Bn |
| Jun 30, 2024 | 3.89 Bn |
| Dec 31, 2023 | 10.21 Bn |
| Dec 31, 2023 | 10.21 Bn |
| Jun 30, 2023 | 4.77 Bn |
| Jun 30, 2023 | 4.77 Bn |
| Dec 31, 2022 | 11.46 Bn |
| Dec 31, 2022 | 11.46 Bn |
| Jun 30, 2022 | 5.19 Bn |
| Jun 30, 2022 | 5.19 Bn |
| Dec 31, 2021 | 10.43 Bn |
| Dec 31, 2021 | 10.43 Bn |
| Jun 30, 2021 | 5.05 Bn |
| Jun 30, 2021 | 5.05 Bn |
| Dec 31, 2020 | 54.73 Mn |
| Dec 31, 2020 | 54.73 Mn |
| Jun 30, 2020 | 4.76 Bn |
| Jun 30, 2020 | 4.76 Bn |